SCHEMBL279955

SCHEMBL279955

Cc1ccc(C(=O)N2CCC(N)C2)s1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.56
ALDH1A1 P00352 4/20 0.56
LMNA P02545 1/20 0.49
GAA P10253 1/20 0.49
SLC18A3 Q16572 3/20 0.47
L3MBTL3 Q96JM7 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
YEATS4 O95619 1/20 0.42
KDM4E B2RXH2 1/20 0.42
DAO P14920 1/20 0.42
KDM1A O60341 1/20 0.41
HTR7 P34969 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
PARP1 P09874 1/20 0.39
PARP2 Q9UGN5 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14625164 0.84 HPGD (0.57) HPGDALDH1A1LMNAGAASLC18A3
SCHEMBL12265875 0.83 YEATS4 (0.65) HPGDALDH1A1LMNAL3MBTL3L3MBTL1
SCHEMBL9921710 0.82 HPGD (0.56) HPGDALDH1A1LMNAGAASLC18A3
SCHEMBL279839 0.80 ALDH1A1 (0.53) HPGDALDH1A1LMNAGAASLC18A3
SCHEMBL280089 0.78 ALDH1A1 (0.51) HPGDALDH1A1LMNAGAASLC18A3
SCHEMBL280027 0.77 SLC18A3 (0.50) HPGDALDH1A1LMNAGAASLC18A3
SCHEMBL328077 0.77 ALDH1A1 (0.50) HPGDALDH1A1LMNAGAASLC18A3
SCHEMBL9918291 0.77 ALDH1A1 (0.50) HPGDALDH1A1LMNAGAASLC18A3
SCHEMBL9918314 0.77 ALDH1A1 (0.50) HPGDALDH1A1LMNAGAASLC18A3
SCHEMBL21230300 0.77 HPGD (0.59) HPGDALDH1A1LMNAGAASLC18A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL HPGD 1895/4885ALDH1A1 2047/4885LMNA 1745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.